GSK Settles 93% of US Zantac Lawsuits for $2.2B
Ticker: GLAXF · Form: 6-K · Filed: Oct 9, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 9, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $2.2 billion, $70 million, $70 million, $2.3 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: litigation, settlement, pharmaceuticals, legal
TL;DR
GSK is paying up to $2.2B to settle ~80k Zantac cases, clearing 93% of US state court litigation.
AI Summary
GSK plc announced on October 9, 2024, that it has reached settlement agreements to resolve approximately 93% of U.S. state court Zantac product liability cases, totaling around 80,000 cases. The total cost for these settlements is expected to be up to $2.2 billion.
Why It Matters
This settlement significantly reduces GSK's legal exposure related to Zantac, potentially removing a major overhang for investors and allowing the company to focus on future growth.
Risk Assessment
Risk Level: medium — While the settlement resolves a large portion of the litigation, the substantial dollar amount and the remaining 7% of cases still present financial and legal risks.
Key Numbers
- $2.2B — Zantac Litigation Settlement (Maximum amount GSK will pay to resolve approximately 80,000 U.S. state court cases.)
- 93% — Zantac Cases Resolved (Proportion of U.S. state court Zantac product liability cases covered by the settlement agreements.)
- 80,000 — Zantac Cases Resolved (Approximate number of U.S. state court Zantac product liability cases included in the settlement.)
Key Players & Entities
- GSK plc (company) — Registrant and defendant in Zantac litigation
- Zantac (product) — Drug at the center of product liability lawsuits
- ranitidine (drug_name) — The active ingredient in Zantac
- $2.2 billion (dollar_amount) — Maximum settlement amount for Zantac litigation
- 80,000 (number) — Approximate number of Zantac cases to be resolved
- 93% (percentage) — Percentage of U.S. state court Zantac cases being settled
- October 9, 2024 (date) — Date of the announcement
FAQ
What is the total number of Zantac cases GSK is settling?
GSK is settling approximately 80,000 U.S. state court Zantac product liability cases.
What is the maximum financial exposure for GSK from these Zantac settlements?
The settlement agreements are for up to $2.2 billion.
What percentage of U.S. state court Zantac cases does this settlement cover?
The settlement agreements resolve approximately 93% of the U.S. state court Zantac product liability cases.
When was this settlement announcement made?
The announcement was made on October 9, 2024.
Does this settlement cover all Zantac litigation?
No, this settlement covers approximately 93% of U.S. state court Zantac product liability cases, leaving 7% of such cases unresolved.
Filing Stats: 839 words · 3 min read · ~3 pages · Grade level 12.5 · Accepted 2024-10-09 13:29:17
Key Financial Figures
- $2.2 billion — antac product liability cases for up to $2.2 billion ● Separate settlement of

- $70 million — nt of  qui tam  complaint for $70 million ● Settlements agreed with no
- $70 million — greement in principle to pay a total of $70 million to resolve the Zantac  qui tam &#x
- $2.3 billion — Results for 2024 of £1.8 billion ($2.3 billion) in relation to the State Courts Settle
Filing Documents
- a6112h.htm (6-K) — 37KB
- 0001654954-24-012809.txt ( ) — 38KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: October 09, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc